A single centre, prospective, open-label, parallel group, randomized study to compare the gastrointestinal tolerability of mycophenolate mofetil (MMF, CellCept) and enteric-coated mycophenolate sodium (EC-MPS, Myfortic) in maintenance transplant patients treated with calcineurin inhibitors

Trial Profile

A single centre, prospective, open-label, parallel group, randomized study to compare the gastrointestinal tolerability of mycophenolate mofetil (MMF, CellCept) and enteric-coated mycophenolate sodium (EC-MPS, Myfortic) in maintenance transplant patients treated with calcineurin inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
  • Indications Heart transplant rejection; Kidney-pancreas transplant rejection; Liver transplant rejection; Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MOTOR-MPA
  • Most Recent Events

    • 13 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top